Cormorant Asset Management, LP Crispr Therapeutics Ag Transaction History

Cormorant Asset Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$110.72 - $210.04 $22.1 Million - $42 Million	-200,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$79.67 - $173.23 $7.97 Million - $17.3 Million	-100,000 Reduced 33.33%	200,000 $30.6 Million
Q3 2020 Nov 16, 2020	SELL	$78.5 - $100.64 $7.85 Million - $10.1 Million	-100,000 Reduced 25.0%	300,000 $25.1 Million
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $8.87 Million - $17.5 Million	-230,400 Reduced 36.55%	400,000 $29.4 Million
Q1 2020 May 15, 2020	SELL	$33.68 - $62.53 $12.4 Million - $23.1 Million	-369,600 Reduced 36.96%	630,400 $26.7 Million
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $3.09 Million - $6.16 Million	-84,300 Reduced 7.77%	1,000,000 $60.9 Million
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $15.8 Million - $20.2 Million	384,300 Added 54.9%	1,084,300 $44.4 Million
Q2 2019 Aug 14, 2019	SELL	$35.45 - $48.2 $7.09 Million - $9.64 Million	-200,000 Reduced 22.22%	700,000 $33 Million
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $22.4 Million - $32.7 Million	800,000 Added 800.0%	900,000 $32.1 Million
Q4 2018 Feb 14, 2019	BUY	$22.73 - $42.34 $2.27 Million - $4.23 Million	100,000 New	100,000 $2.86 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.